AbbVie Inc (ABBV)vsKiniksa Pharmaceuticals Ltd (KNSA)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
KNSA
Kiniksa Pharmaceuticals Ltd
$52.99
-1.60%
HEALTHCARE · Cap: $4.08B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8926% more annual revenue ($61.16B vs $677.56M). KNSA leads profitability with a 8.7% profit margin vs 6.9%. KNSA trades at a lower P/E of 58.2x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
KNSA
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+77.8%
Fair Value
$202.90
Current Price
$52.99
$149.91 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 65.0% year-over-year
Earnings expanding 550.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 58.2x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while KNSA is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 51/100). KNSA offers better value entry with a 77.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a commitment to redefining treatment paradigms, Kiniksa presents a compelling opportunity for institutional investors seeking exposure in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?